Moreover, ezetimibe improves not only lipid profiles, but also atherogenic factors and biomarkers, such as hepatocyte growth factor and insulin resistance, in patients with obesity and hypercholesterolemia [20]. Here, HGF is linked to obesity due to melanocortin 4 receptor deficiency.